Harnessing the Potential of Artificial Intelligence in Managing Viral Hepatitis

Abstract

Viral hepatitis continues to be a serious global health concern, impacting millions of people, putting a strain on healthcare systems across the world, and causing significant morbidity and mortality. Traditional diagnostic, prognostic, and therapeutic procedures to address viral hepatitis are successful but have limits in accuracy, speed, and accessibility. Artificial intelligence (AI) advancement provides substantial opportunities to overcome these challenges. This study investigates the role of AI in revolutionizing viral hepatitis care, from early detection to therapy optimization and epidemiological surveillance. A comprehensive literature review was conducted using predefined keywords in the Nature, PLOS ONE, PubMed, Frontiers, Wiley Online Library, BMC, Taylor & Francis, Springer, ScienceDirect, MDPI, IEEE Xplore Digital Library, and Google Scholar databases. Peer-reviewed publications written in English between January 2019 and August 2024 were examined. The data of the selected research papers were synthesized and analyzed using thematic and narrative analysis techniques. The use of AI-driven algorithms in viral hepatitis control involves many significant aspects. AI improves diagnostic accuracy by integrating machine learning (ML) models with serological, genomic, and imaging data. It enables tailored treatment plans by assessing patient-specific characteristics and predicting therapy responses. AI-powered technologies aid in epidemiological modeling, and AI-powered systems effectively track treatment adherence, identify medication resistance, and control complications associated with chronic hepatitis infections. It is vital in identifying new antiviral medicines and vaccines, speeding the development pipeline through high-throughput screening and predictive modeling. Despite its transformational promise, using AI in viral hepatitis care presents various challenges, including data privacy concerns, the necessity for extensive and varied datasets, and the possibility of algorithmic biases. Ethical considerations, legal frameworks, and multidisciplinary collaboration are required to resolve these issues and ensure AI technology’s safe and successful use in clinical practice. Exploiting the full AI’s potential for viral hepatitis management provides unparalleled prospects to improve patient outcomes, optimize public health policies, and, eventually, and alleviate the disease’s negative impact worldwide. This study seeks to provide academics, medics, and policymakers with the fundamental knowledge they need to harness AI’s potential in the fight against viral hepatitis.